Free what is obstructive sleep apnea Topical Map Generator

OSA is diagnosed by measuring the apnea–hypopnea index (AHI) during sleep using either in-lab polysomnography (PSG) or an accredited home sleep apnea test (HSAT). PSG is the gold standard and required when comorbid conditions (neuromuscular disease, suspected central sleep apnea, or significant cardiopulmonary disease) are present; HSAT is validated for diagnosing moderate-to-severe OSA in uncomplicated adults.

AHI is the number of apneas plus hypopneas per hour of sleep: 5–14.9 is mild OSA, 15–29.9 is moderate, and ≥30 is severe. Treatment decisions incorporate AHI plus symptoms, cardiovascular risk, and comorbidities rather than AHI alone.

Choose HSAT for adults with a high pretest probability of moderate-to-severe OSA who lack major comorbidities (no heart failure, neuromuscular disease, or suspected central apnea). If HSAT is negative but clinical suspicion remains high—or if results are inconclusive—proceed to in-lab PSG.

CPAP is first-line therapy for moderate-to-severe OSA and for symptomatic patients with mild OSA who prefer it or have significant cardiometabolic risk. Patients with excessive daytime sleepiness, occupational risk (e.g., commercial drivers), or comorbid hypertension/CV disease typically derive the clearest benefit.

Many patients notice reduced daytime sleepiness and better concentration within days to weeks when using CPAP consistently for several hours each night. Objective cardiovascular benefits (blood pressure reduction, improved glycemic control) usually require weeks to months of regular use to appear.

Good adherence is commonly defined as ≥4 hours/night on ≥70% of nights during an evaluation window; this threshold is used by many insurers for ongoing coverage. Real-world data show only about 50–60% of patients meet that benchmark in the first 3 months without targeted adherence support.

Yes: try mask resizing or a different mask style for leaks; add heated humidification or a full-face mask for dry mouth; use ramp pressure, desensitization exercises, and shorter successful practice sessions to manage claustrophobia. If problems persist after basic adjustments, remote or clinic-based CPAP coaching within the first 2–4 weeks significantly increases long-term use.

Observational studies link untreated moderate–severe OSA to roughly double the risk of hypertension and increased stroke risk, and CPAP improves blood pressure and surrogate markers. However, large randomized trials (e.g., SAVE) did not show a clear reduction in major cardiovascular events in all-comers—benefit appears greatest in symptomatic, adherent patients and certain high-risk subgroups.

Fixed CPAP delivers continuous single pressure; APAP automatically adjusts pressure night-to-night to respond to flow limitations and snoring, useful for variable needs or during titration; BiPAP provides different inspiratory and expiratory pressures and is reserved for patients who cannot tolerate CPAP, have high pressure requirements, or have coexisting hypoventilation or complex sleep-disordered breathing.

In many markets, durable medical equipment coverage requires documentation of OSA and a demonstration of adherence (commonly ≥4 hours/night on 70% of nights within an initial evaluation period) for long-term coverage; out-of-pocket costs vary widely—basic machines can be <$300 with insurance or $500–$2,000 retail. Mask replacements and supplies are recurring costs, but many insurers cover routine replacement on a scheduled basis.